Study of Crenolanib in Recurrent/Refractory Glioblastoma With PDGFRA Gene Amplification
Status:
Completed
Trial end date:
2020-07-01
Target enrollment:
Participant gender:
Summary
This is a proof of concept, single-arm study to investigate crenolanib monotherapy in
patients with recurrent/refractory glioblastoma with PDGFRA gene amplification by assessing
the progression-free survival (PFS) at 6 months. Crenolanib will be given orally starting at
100 mg TID continuously until disease progression, unacceptable toxicity, or consent
withdrawal.